Saturday 17 October 2026
Export ALLR’s income statement to Excel — free account
Allarity Therapeutics, Inc.
ALLR Healthcare Biotechnology
Allarity Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $320,000.00. In the quarter to June 2026, EPS fell 40.0%, free cash flow grew 53.2% and total debt rose 3.56%, each against the same quarter a year earlier.
0.90
0.07
+8.43%
Follow ALLR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(10.51) | — | — | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(23.25) | — | — | — | — | — | (6.15) | (1.14) | — | — |
P/FCF ratio |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(4.79) | — | — | — | — | — | (18,313,192.29) | (18,313,192.29) | (18,313,192.29) | (18,313,192.29) |
P/B ratio |
1.58 | — | — | — | — | — | 2,305,433.40 | 2,305,433.40 | 2,305,433.40 | 2,305,433.40 |
Price to Tangible BV |
57.30 | — | — | — | — | — | 74,570,839.69 | 74,570,839.69 | 74,570,839.69 | 74,570,839.69 |
EV/Sales |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.23) | — | — | — | — | — | (5,257,685.33) | (5,257,685.33) | (5,257,685.33) | (5,257,685.33) |
EV/FCF |
(0.23) | — | — | — | — | — | (5,257,685.33) | (5,257,685.33) | (5,257,685.33) | (5,257,685.33) |
Quick Ratio |
1.85 | 2.00 | 0.07 | 0.25 | 1.00 | 0.22 | 0.67 | 0.35 | 0.67 | 2.58 |
Current Ratio |
2.13 | 2.06 | 0.14 | 0.44 | 1.03 | 0.31 | 0.71 | 0.41 | 0.77 | 2.71 |
Net Debt/EBITDA |
1.05 | 1.04 | (0.07) | (0.10) | 0.72 | (0.23) | 0.06 | (0.44) | 0.12 | 0.36 |
Debt/Assets |
7.67% | 5.96% | 10.96% | 25.63% | 1.99% | 6.61% | 3.05% | 7.51% | 0.00% | 0.00% |
Debt/Equity |
0.14 | 0.11 | (0.47) | (32.98) | 0.05 | 0.09 | 0.05 | 0.12 | 0.00 | 0.00 |
Asset Turnover |
0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.70 | 0.28 |
Operating CF/Net income |
1.32 | 0.69 | 0.62 | 0.80 | 0.56 | 1.10 | 0.71 | 1.85 | 0.27 | 0.74 |
Capex/Depreciation |
0.62 | (0.03) | 0.00 | 0.00 | 0.00 | (0.07) | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(68.14) | (41.72) | (34.40) | (154.54) | (53.22) | (26.00) | (6.10) | (35.35) | — | — |
| (103.80%) | (687.46%) | 886.50% | (233.39%) | (125.13%) | (50.05%) | (12.09%) | (19.21%) | (479.08%) | (158.64%) | |
| (54.91%) | (145.77%) | (154.63%) | (65.60%) | (64.18%) | (35.88%) | (7.41%) | (11.35%) | (412.00%) | (71.91%) | |
ROIC |
0.00% | 0.00% | 0.00% | (1,358.95%) | 0.00% | (19.73%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(114.28%) | (212.97%) | 167.67% | 337.73% | (3,845.31%) | 173.87% | 1,524.28% | 73.38% | 1,294.46% | (126.29%) |
Average Days of Receivables |
987.78 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5,037.00 | 1,806.64 | 269.60 | 637.21 |
Research and Development Expense of Revenue |
2,062.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5,305.83% | 1,834.89% | 309.84% | 321.30% |
Selling, General and Administrative Expense of Revenue |
1,976.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,154.17% | (1,834.89%) | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.83 | 0.66 | 0.57 | 0.91 | 0.88 | 0.94 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
213.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.61 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(74.07%) | — | — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow Yield |
(97.54%) | — | — | — | — | — | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | 0.39 | 1.34 | 1.05 |
Operating CF per Share |
(1.03) | (10.80) | (3,748.53) | 0.00 | (2.34) | (2.22) | (24.00) | (4.96) | (2.17) | (2.01) |
Capex per Share |
0.00 | (0.19) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.03) | (10.98) | (3,748.53) | 0.00 | (2.34) | (2.22) | (24.00) | (4.96) | (2.17) | (2.01) |
Cash per Share |
1.02 | 12.15 | 48.82 | 0.00 | 3.13 | 0.09 | 3.62 | 0.27 | 0.88 | 1.33 |
Shareholders Equity per Share |
0.68 | 7.35 | (809.12) | 0.00 | 2.85 | 7.49 | 42.93 | 27.46 | 0.65 | 2.74 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.68 | 7.35 | (809.12) | 0.00 | 2.85 | 7.49 | 42.93 | 27.46 | 0.65 | 2.74 |
Free Cash Flow |
(14.83) | (17.65) | (12.74) | (16.83) | (14.89) | (7.25) | (1.09) | (4.25) | (1.32) | (1.18) |
Working Capital |
9.50 | 11.50 | (12.20) | (6.25) | 0.69 | (3.82) | (0.15) | (3.18) | (0.39) | 1.23 |
Capital Expenditures |
(0.01) | (0.30) | — | (0.02) | — | 0.00 | 0.00 | (0.13) | — | (0.01) |
Net Current Asset Value |
9.50 | 11.50 | (12.64) | (9.69) | (10.08) | (7.25) | (0.79) | (8.37) | (0.39) | 1.23 |
EV/EBIT |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(0.04) | 31.43 | 1.85 | 839.57 | 13.25 | 2.19 | 0.19 | 0.59 | 0.39 | 0.23 |
Cash ROIC |
(57.22%) | (53.99%) | 991.83% | (298.33%) | (38.12%) | (26.92%) | (49.15%) | (15.95%) | (141.85%) | (49.43%) |
Accounts Receivable Turnover |
0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.30 | 0.97 | 0.74 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.51 | 8.39 | 2.56 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 20.36 | 6.20 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 109.37 | 55.07 | 104.70 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 22.99 | 42.22 |
Average Receivables |
1.53 | 1.50 | 0.80 | 0.81 | 0.87 | 0.54 | 0.91 | 1.12 | 0.84 | 0.84 |
Average Payables |
4.23 | 6.30 | 7.33 | 3.47 | 1.41 | 2.16 | 2.06 | 1.16 | 0.32 | 0.32 |
Average Inventory |
— | — | — | — | — | — | — | — | 0.13 | 0.13 |
Average Assets |
20.45 | 17.26 | 13.20 | 32.09 | 41.52 | 18.40 | 20.76 | 20.22 | 1.16 | 2.21 |
Average Common Equity |
10.82 | 3.66 | (2.30) | 9.02 | 21.30 | 13.19 | 12.73 | 11.96 | 1.00 | 1.00 |
Columns are period end dates